|

Pegcetacoplan Clinical Trials

2 actively recruiting trials across 1 location

Also known as: APL 2, APL-2, APL2, Empaveli

Pipeline

Phase 2: 1Phase 1/2: 1

Top Sponsors

  • Roswell Park Cancer Institute2

Indications

  • Cancer2
  • Fallopian Tube Serous Adenocarcinoma1
  • Fallopian Tube Endometrioid Adenocarcinoma1
  • Recurrent Ovarian Carcinoma1
  • Primary Peritoneal Carcinosarcoma1

Buffalo, New York2 trials

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion

Roswell Park Cancer Institute

Phase 2
Pegcetacoplan in Combination With Modified FOLFIRINOX for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Roswell Park Cancer Institute

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.